FDA Clarifies Label Warning For Acetaminophen Liver Damage
This article was originally published in The Tan Sheet
Executive Summary
The agency seeks to clarify potential confusion for consumers linked to label statements about the level of acetaminophen that can pose a threat. FDA proposes an alternative warning to be used on labels of some acetaminophen-containing products.
You may also be interested in...
OTC Acetaminophen Label Guidance For Liver Warning Clarifies Ingredient Specifics
FDA allows marketers of acetaminophen-containing OTC products to use an alternative liver warning, according to an updated guidance. The change from the draft, which aligns with a request by CHPA, separates maximum dosage for the ingredient from the dosage included in a certain product.
OTC Acetaminophen Label Guidance For Liver Warning Clarifies Ingredient Specifics
FDA allows marketers of acetaminophen-containing OTC products to use an alternative liver warning, according to an updated guidance. The change from the draft, which aligns with a request by CHPA, separates maximum dosage for the ingredient from the dosage included in a certain product.
Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”
The most popular stories in “The Tan Sheet” during 2012 dealt with FDA’s nonprescription safe use regulatory extension initiative, as well as planned switches by Pfizer and Merck. In dietary supplements, coverage of firms struggling with GMPs and congressional threats to DSHEA drew the most interest.